BMO Capital lowered the firm’s price target on MacroGenics to $5 from $8 and keeps a Market Perform rating on the shares. The quarter was in line with expectations following the vobra duonews last week, though the firm also removed vobra duo contribution in prostate cancer as it does not believe the risk/benefit profile for the molecule can be competitive in this indication, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
- MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
- MacroGenics downgraded to Neutral from Buy at BTIG
- MacroGenics price target lowered to $8 from $16 at JMP Securities
- MacroGenics price target lowered to $8 from $9 at Barclays
- MacroGenics downgraded to Neutral from Buy at Guggenheim